Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - water for injections, quantity: 5.4 ml - injection, solution - excipient ingredients: - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for:,? control and prevention of bleeding episodes,? routine prophylaxis to prevent or reduce the frequency of bleeding episodes,? perioperative management (surgical prophylaxis),adynovate is not indicated for the treatment of von willebrand disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - water for injections, quantity: 5.4 ml - injection, solution - excipient ingredients: - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for:,? control and prevention of bleeding episodes,? routine prophylaxis to prevent or reduce the frequency of bleeding episodes,? perioperative management (surgical prophylaxis),adynovate is not indicated for the treatment of von willebrand disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - water for injections, quantity: 5.4 ml - injection, solution - excipient ingredients: - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for:,? control and prevention of bleeding episodes,? routine prophylaxis to prevent or reduce the frequency of bleeding episodes,? perioperative management (surgical prophylaxis),adynovate is not indicated for the treatment of von willebrand disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - water for injections, quantity: 5.4 ml - injection, solution - excipient ingredients: - adynovate is a long-acting antihaemophilic factor (recombinant) indicated in haemophilia a (congenital factor viii deficiency) patients for:,? control and prevention of bleeding episodes,? routine prophylaxis to prevent or reduce the frequency of bleeding episodes,? perioperative management (surgical prophylaxis),adynovate is not indicated for the treatment of von willebrand disease.

European Union - English - EMA (European Medicines Agency)

baxalta innovations gmbh - rurioctocog alfa pegol - hemophilia a - antihemorrhagics - treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia a (congenital factor viii deficiency).

European Union - English - EMA (European Medicines Agency)

novo nordisk a/s - turoctocog alfa pegol - hemophilia a - antihemorrhagics - treatment and prophylaxis of bleeding in patients 12 years and above with haemophilia a (congenital factor viii deficiency).

Israel - English - Ministry of Health

novo nordisk ltd., israel - turoctocog alfa pegol - powder and solvent for solution for injection - turoctocog alfa pegol 1000 iu/vial - treatment and prophylaxis of bleeding in previously treated patients with haemophilia a (congenital factor viii disorder).esperoct® does not contain pharmacologically active quantities of von willebrand factor and is, therefore, unsuitable for the treatment of von willebrand disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - turoctocog alfa pegol, quantity: 3000 iu - injection, solvent for - excipient ingredients: sodium chloride; water for injections - esperoct, is a long-acting recombinant factor viii concentrate indicated for use in previously treated patients with haemophilia a for:,? routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes,? on-demand treatment and control of bleeding episodes,? peri-operative management of bleeding (surgical prophylaxis),esperoct does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand?s disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - turoctocog alfa pegol, quantity: 500 iu - injection, solvent for - excipient ingredients: sodium chloride; water for injections - esperoct, is a long-acting recombinant factor viii concentrate indicated for use in previously treated patients with haemophilia a for:,? routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes,? on-demand treatment and control of bleeding episodes,? peri-operative management of bleeding (surgical prophylaxis),esperoct does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand?s disease.

Australia - English - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - turoctocog alfa pegol, quantity: 1000 iu - injection, solvent for - excipient ingredients: water for injections; sodium chloride - esperoct, is a long-acting recombinant factor viii concentrate indicated for use in previously treated patients with haemophilia a for:,? routine prophylactic treatment to prevent or reduce the frequency of bleeding episodes,? on-demand treatment and control of bleeding episodes,? peri-operative management of bleeding (surgical prophylaxis),esperoct does not contain von willebrand factor, and therefore is not indicated in patients with von willebrand?s disease.